Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta‐analysis

Published:2021-01-26 Issue:4 Volume:28 Page:664-671
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Su Xin¹^ORCID,Zhao Xin¹,Deng Jia‐Long¹,Li Song‐Nan¹,Du Xin¹,Dong Jian‐Zeng¹,Ma Chang‐Sheng¹

Affiliation:

1. Department of Cardiology Beijing Anzhen HospitalCapital Medical University Chaoyang District China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13469

Reference48 articles.

1. Hepatitis C

2. Global distribution and prevalence of hepatitis C virus genotypes

3. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden

4. Hepatitis C virus infection and risk of coronary artery disease: A meta-analysis

5. Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon-free hepatitis C treatment increases a surrogate of atherosclerotic cardiovascular disease risk in Black veterans living with HIV;AIDS;2024-06-27

2. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases;The Lancet Diabetes & Endocrinology;2023-09

3. Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States;Pharmacoepidemiology and Drug Safety;2023-06-15

4. Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection;Journal of the American Heart Association;2022-10-04

5. Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals;Journal of Clinical Medicine;2022-09-29